Company Overview
Snapshot
Founded in January 2025, CLISEQ operates with 1–10 employees and has completed two funding rounds. The company is advancing minimally invasive diagnostic approaches for hematologic disorders, leveraging a patented technology from the Weizmann Institute of Science.
Business overview
CLISEQ is a translational diagnostics company specializing in hematology diagnostics. Spun out of the Weizmann Institute of Science, the company develops minimally invasive diagnostic approaches for hematologic disorders using a patented technology that enables peripheral blood single-cell RNA sequencing (scRNA-seq). This technology aims to detect conditions like myelodysplastic syndromes (MDS) as an alternative to bone-marrow aspiration. CLISEQ serves the healthcare and life sciences sectors, focusing on patients and clinical diagnostics.
Strategic signal
In September 2025, CLISEQ announced a collaboration with 10x Genomics and the Weizmann Institute to investigate single-cell applications in hematology clinical diagnostics. This partnership is significant as it validates CLISEQ's technology through an international multi-site clinical trial (PERIBLOOD) involving over 1,500 participants, signaling strong progress towards clinical utility and future diagnostic workflows in hematology.
Log in to access full profile ›Company Intelligence Q&A
- What is CLISEQ's core technology?
- CLISEQ's core technology involves using peripheral blood single-cell RNA sequencing (scRNA-seq) to detect hematologic disorders, such as myelodysplastic syndromes (MDS), offering a minimally invasive alternative to bone-marrow aspiration.
- When was CLISEQ founded?
- CLISEQ was founded in January 2025.
- What is the PERIBLOOD clinical trial?
- The PERIBLOOD clinical trial is an international multi-site study conducted by CLISEQ in partnership with 10x Genomics, Inc. and the Weizmann Institute. It is enrolling over 1,500 participants to validate the clinical utility of CLISEQ's scRNA-seq technology for hematology diagnostics.
- What was a key strategic collaboration for CLISEQ in 2025?
- In September 2025, CLISEQ announced a collaboration with 10x Genomics and the Weizmann Institute to explore single-cell applications in hematology clinical diagnostics.
- What type of funding did CLISEQ receive in January 2025?
- This funding was part of a Pre-Seed round.